External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
Authors:
- 2 January 2020
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 198 (1) , 201-206
Abstract
Purpose In order to personalize multimodal treatment regimens in limited-stage small cell lung cancer (LS-SCLC), a survival score for these patients was proposed. The aim of this study is to validate the score in an independent external patient cohort. Methods We collected data of 78 patients treated with chemoradiotherapy for LS-SCLC between 2004 and 2015. The survival score was calculated by independent prognostic factors: gender, Karnofsky performance status, tumor substage, and hemoglobin level before treatment. Scoring points were derived from 2-year survival rates divided by 10 and the values for each prognostic factor were tallied. Three risk subgroups were defined (high, intermediate, low risk: 9–13, 14–18, 19–26 points). The 2-year survival rate of each subgroup from the original study was compared to its corresponding subgroup from the validation cohort. Results Median survival time in the entire validation cohort was 17 months (range: 1–123 months). The 2-year survival rates were 0% in the 9–13, 35% in the 14–18, and 43% in the 19–26 points group, respectively (p = 0.018). The difference in 2-year survival between the 9–13 points and the 14–18 points group was significant in the validation cohort (p = 0.007) as well after stratification of concurrent chemoradiotherapy (p < 0.001), whereas the difference between the 14 and 18 points and the 19–26 points group was not significant (p = 0.602, p = 0.770). Conclusion The score was reproducible to estimate the 2-year survival rate of patients with LS-SCLC, especially in the high- and intermediate-risk subgroups. In order to improve the differentiation between patients with an intermediate and favorable survival prognosis, the scoring system needs further development.Keywords
This publication has 25 references indexed in Scilit:
- A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung CancersLung, 2016
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?Clinical Cancer Research, 2015
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- A validated scoring system to identify long-term survivors after radiotherapy for metastatic spinal cord compressionStrahlentherapie und Onkologie, 2013
- A validated survival score for breast cancer patients with metastatic spinal cord compressionStrahlentherapie und Onkologie, 2012
- Surgical Resection Should Be Considered for Stage I and II Small Cell Carcinoma of the LungThe Annals of Thoracic Surgery, 2012
- Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on genderThe Clinical Respiratory Journal, 2012
- Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and EtoposideNew England Journal of Medicine, 1999